title: [Use of apomorphine in Parkinson s disease].
abstract: INTRODUCTION. Apomorphine is a D2 dopamine agonist, possibly underused despite its efficacy in situations where other medications have failed or lack of indication for stereotactic surgery. Rapidly effective (between 7 and 10 min) and potency approaching that of levodopa allows apomorphine to reduce reliably severe fluctuations, off period dystonia, biphasic dyskinesias or such symptoms as dysphagia, anismus of micturition difficulties. Unlike other agonists, apomorphine has a modest capacity to induce neuropsychiatric complications. Brief duration of response (<60 min) and the need of subcutaneous administration represent major difficulties in practice. OBJECTIVE and DEVELOPMENT. This review undertake some of the pharmacological properties of this  orphan drug , its use in practice, and new pathways of development
authors.affiliation: Servicio de Neurología, Hospital General Universitario Gregorio Marañon, Madrid, España. sgimenezro@medynet.com
authors.forename: S
authors.initials: S
authors.lastname: Giménez-Roldán
authors.forename: S
authors.initials: S
authors.lastname: García- Muñozguren
mesh_terms: D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001058:Apomorphine / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D001058:Apomorphine